Mirum Pharmaceuticals, Inc.
MIRM
Rank in Stocks
#3225
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Share Price
$85.12
Last synced: 2026-10-20
Market Cap
$5.53B
Change (1 day)
3.50%
Change (1 year)
23.39%
Country
US
Trade Mirum Pharmaceuticals, Inc. (MIRM)
Category
Healthcare
Revenue for Mirum Pharmaceuticals, Inc. (MIRM)
Revenue in Jun 2026 TTM: $618.07M
According to Mirum Pharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is $618.07M. In 2023 the company made a revenue of $186.37M an increase over the revenue in the year 2022 that was $77.06M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Mirum Pharmaceuticals, Inc. from 2018 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $618.07M | 83.46% |
| 2024 | $336.89M | 80.76% |
| 2023 | $186.37M | 141.85% |
| 2022 | $77.06M | 302.66% |
| 2021 | $19.14M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 1,942.55% |
US
|
|
| $2.23B | 260.48% |
US
|
|
| $15.74B | 2,447.35% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 874.21% |
NL
|
